Avenue Therapeutics Announces Positive Topline Data from Second Pivotal Phase 3 Study of Intravenous Tramadol in the Management of Postoperative Pain

NEXT STORY
Myriad Genetics Announces New Results from Two Large Studies of Its myRisk® Hereditary Cancer Test at American Society of Clinical Oncology
PREV STORY
Oncology Venture receives response from the FDA to the IND-application and proposed pivotal study for LiPlaCis
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Aptose Presents New Preclinical Data on CG’806 Pan-FLT3/ Pan-BTK Inhibitor at 2018 AACR Annual Meeting

author_avatar
NASDAQ Market News

Atea Pharmaceuticals Announces IND Clearance of AT-527 for COVID-19 and $215 Million Financing

author_avatar
NASDAQ Market News

VBL Therapeutics Announces Upcoming Presentations on VB-111 at the ASCO and ASGCT 2017 Conferences

TEL AVIV, Israel, April 25, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), announced that ...

author_avatar
NASDAQ Market News